Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spruce Biosciences, Inc. (SPRB : NSDQ)

• Company Description    Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $87.11 Daily Weekly Monthly 20 Day Moving Average: 48,007 shares Shares Outstanding: 1.07 (millions) Market Capitalization: $93.24 (millions) Beta: 3.57 52 Week High: $240.00 52 Week Low: $0.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.68% -3.52% 12 Week -50.31% -51.11% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 611 GATEWAY BOULEVARD SUITE 740 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 415-655-4168 fax: - investors@sprucebio.com http://www.sprucebiosciences.com

• General Corporate Information    Officers Javier Szwarcberg - Chief Executive Officer Michael Grey - Executive Chairman Samir Gharib - President and Chief Financial Officer Tiba Aynechi - Director Percival Barretto-Ko - Director Peer Information Spruce Biosciences, Inc. (CORR.) Spruce Biosciences, Inc. (RSPI) Spruce Biosciences, Inc. (CGXP) Spruce Biosciences, Inc. (BGEN) Spruce Biosciences, Inc. (GTBP) Spruce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 85209E208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 04/21/26 Share - Related Items Shares Outstanding: 1.07 Most Recent Split Date: 8.00 (0.01:1) Beta: 3.57 Market Capitalization: $93.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-12.99 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-41.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/21/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.12 Price/Cash Flow: - Price / Sales: 18.99 EPS Growth vs. Year Ago Period: 7.66% vs. Previous Quarter: -316.57% Sales Growth vs. Year Ago Period: -75.86% vs. Previous Quarter: 15.78% ROE 12/31/25 - - 09/30/25 - -305.39 06/30/25 - -177.45 ROA 12/31/25 - - 09/30/25 - -168.01 06/30/25 - -118.06 Current Ratio 12/31/25 - - 09/30/25 - 1.54 06/30/25 - 2.60 Quick Ratio 12/31/25 - - 09/30/25 - 1.54 06/30/25 - 2.60 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -6,869.30 06/30/25 - -3,721.17 Book Value 12/31/25 - - 09/30/25 - 10.73 06/30/25 - 23.47 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©